Abstract
Objectives To develop and validate a deep learning (DL) based primary tumor biopsy signature for predicting axillary lymph node (ALN) metastasis preoperatively in early breast cancer (EBC) patients with clinically negative ALN.
Methods A total of 1058 EBC patients with pathologically confirmed ALN status were enrolled from May 2010 to August 2020. A deep learning core-needle biopsy (DL-CNB) model was built on the attention based multiple instance learning (AMIL) framework to predict ALN status utilizing the deep learning features, which were extracted from the cancer areas of digitized whole-slide images (WSIs) of breast CNB specimens annotated by two pathologists. Accuracy, sensitivity, specificity, receiver operating characteristic (ROC) curves, and areas under the receiver operating characteristic curve (AUCs) were analyzed to evaluate our model.
Results The best performing DL-CNB model with VGG16_BN as the feature extractor achieved an AUC of 0.816 (95% confidence interval (CI): 0.758, 0.865) in predicting positive ALN metastasis in the independent test cohort. Furthermore, our model incorporating the clinical data, which was called DL-CNB+C, yielded the best accuracy of 0.831 (95%CI: 0.775, 0.878), especially for patients younger than 50 years (AUC: 0.918, 95%CI: 0.825, 0.971). The interpretation of DL-CNB model showed that the top signatures most predictive of ALN metastasis were characterized by the nuclei features including density (p=0.015), circumference (p=0.009), circularity (p=0.010), and orientation (p=0.012).
Conclusion Our study provides a novel deep learning-based biomarker on primary tumor CNB slides to predict the metastatic status of ALN preoperatively for patients with early breast cancer.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by National Natural Science Foundation of China [No. 8197101438].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Beijing Chao-Yang Hospital, Capital Medical University gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Competing interests The authors declared no competing interests existing in this work.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
